STUDY OF POTENTIAL MUTAGENIC PROPERTIES OF THE DRUG DIOMAST-KRS
The article presents the results of studying mutagenic activity of the two-component drug Diomast-KRS (component 1 - recombinant bovine cytokines and vitamin A, component 2 - dioxidine and vitamin A), and its components separately with a single injection by means of a micronucleus test. White laboratory mice (n=36) were selected for the experiment. They were divided into 6 groups, 6 individuals in each one. It has been found that a single use of the drug Diomast-KRS at therapeutic and high doses (1/10 of LD<sub>50</sub>) does not cause statistically significant deviations in the number of micronuclei and the percentage of polychromatophilic erythrocytes in the bone marrow of white laboratory mice relative to the control values. The components of the drug used separately also did not cause changes in cytogenetic stability in the bone marrow cells of mice. Thus, the drug Diomast-KRS does not have a pronounced mutagenic effect at the tested doses.